← Back to Screener
ProQR Therapeutics N.V. Ordinary Shares (PRQR)
Price$1.95
Favorite Metrics
Price vs S&P 500 (26W)-19.66%
Price vs S&P 500 (4W)9.88%
Market Capitalization$239.51M
All Metrics
Book Value / Share (Quarterly)$0.54
P/TBV (Annual)5.61x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)50.45%
Cash Flow / Share (Quarterly)$-0.59
Price vs S&P 500 (YTD)-4.13%
Net Profit Margin (TTM)-258.05%
EPS (TTM)$-0.47
10-Day Avg Trading Volume0.75M
EPS Excl Extra (TTM)$-0.47
Revenue Growth (5Y)11.58%
EPS (Annual)$-0.47
ROI (Annual)-64.56%
Net Profit Margin (5Y Avg)-923.85%
Cash / Share (Quarterly)$1.01
Revenue Growth QoQ (YoY)6.14%
ROA (Last FY)-37.41%
Revenue Growth TTM (YoY)-16.36%
EBITD / Share (TTM)$-0.46
ROE (5Y Avg)-67.66%
Operating Margin (TTM)-265.77%
Cash Flow / Share (Annual)$-0.59
P/B Ratio3.50x
P/B Ratio (Quarterly)3.66x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)5.89x
Net Interest Coverage (TTM)-13.09x
ROA (TTM)-32.06%
EPS Incl Extra (Annual)$-0.47
Current Ratio (Annual)3.09x
Quick Ratio (Quarterly)3.01x
3-Month Avg Trading Volume0.51M
52-Week Price Return68.64%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.54
P/S Ratio (Annual)10.57x
Asset Turnover (Annual)0.14x
52-Week High$3.10
Operating Margin (5Y Avg)-899.36%
EPS Excl Extra (Annual)$-0.47
CapEx CAGR (5Y)2.09%
Tangible BV CAGR (5Y)10.74%
26-Week Price Return-15.68%
Quick Ratio (Annual)3.01x
13-Week Price Return18.45%
Total Debt / Equity (Annual)0.32x
Current Ratio (Quarterly)3.09x
Enterprise Value$113.393
Revenue / Share Growth (5Y)-3.84%
Asset Turnover (TTM)0.12x
Book Value / Share Growth (5Y)-15.36%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-257.94%
Cash / Share (Annual)$1.01
3-Month Return Std Dev75.13%
Net Income / Employee (TTM)$-0
ROE (Last FY)-85.44%
Net Interest Coverage (Annual)-21.33x
EPS Basic Excl Extra (Annual)$-0.47
P/FCF (TTM)13.26x
Receivables Turnover (TTM)32.56x
Total Debt / Equity (Quarterly)0.32x
EPS Incl Extra (TTM)$-0.47
Receivables Turnover (Annual)0.17x
ROI (TTM)-52.97%
P/S Ratio (TTM)10.57x
Pretax Margin (5Y Avg)-921.60%
Revenue / Share (Annual)$0.18
Tangible BV / Share (Annual)$2.54
Price vs S&P 500 (52W)38.81%
Year-to-Date Return-1.49%
5-Day Price Return0.51%
EPS Normalized (Annual)$-0.47
ROA (5Y Avg)-28.35%
Net Profit Margin (Annual)-258.05%
Month-to-Date Return22.84%
Cash Flow / Share (TTM)$-0.51
EBITD / Share (Annual)$-0.46
Operating Margin (Annual)-265.77%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-49.32%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.47
P/TBV (Quarterly)5.61x
P/B Ratio (Annual)3.66x
Pretax Margin (TTM)-257.94%
Book Value / Share (Annual)$0.54
Price vs S&P 500 (13W)17.76%
Beta0.20x
P/FCF (Annual)8.56x
Revenue / Share (TTM)$0.18
ROE (TTM)-66.86%
52-Week Low$1.08
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PRQRProQR Therapeutics N.V. Ordinary Shares | 10.57x | -16.36% | — | — | $1.95 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
ProQR Therapeutics NV develops RNA-based therapeutics for severe genetic rare diseases, including cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The company's entire research and development effort is dedicated to discovering and advancing RNA therapeutics.